Survival of malignant plasma cells is a key event in disease occurrence, progression and chemoresistance. Using DNA-microarrays, we analysed the expression of genes coding for 58 proteins linked with extrinsic and intrinsic apoptotic pathways, caspases and inhibitor of apoptosis proteins. We considered 6 memory B cells (MBC), 7 plasmablasts (PPC), 7 bone marrow plasma cells (BMPC) and purified myeloma cells 
Introduction
Multiple myeloma (MM) is a B cell neoplasia characterized by accumulation of clonal plasma cells, i.e. multiple myeloma cells (MMC), in the bone marrow. This accumulation depends both on survival and proliferation of MMC. Several genetic abnormalities in MM target cell cycle genes: CCND1, CCND3, CKS1B (Fonseca, et al 2004; Avet-Loiseau, et al 2007) . Other abnormalities, t(4;14) or t(14;16), result in high cyclin D2 expression (Bergsagel, et al 2005) . The percentage of proliferating MMC is usually low, but is nevertheless a powerful adverse prognostic factor (Greipp, et al 1988) . Besides an increased proliferation, the survival of MMC is a prior and an essential condition to allow the accumulation of clonal plasma cells. In patients with intramedullary MM, the survival of MMC is strictly dependent upon the interaction with bone marrow (BM) stromal cells and/or osteoclasts (Uchiyama, et al 1993; Yaccoby, et al 2004) . When purified in vitro, MMC rapidly apoptose, but addition of BM stromal cells can rescue them from apoptosis (Gu, et al 2000) . Several growth factors are involved in this MMC/stromal cell interactions, including IL-6 (Zhang, et al 1992) , IGF-1 (Ferlin, et al 2000) , IL-10 (Gu, et al 1996) , EGF family members (Mahtouk, et al 2004; Mahtouk, et al 2005) , BAFF/APRIL (Moreaux, et al 2004) , IFN- (Ferlin-Bezombes, et al 1998) , HGF (Derksen, et al 2003) , Wnt family members (Derksen, et al 2004) , IL-21 (Brenne, et al 2002) , and Jagg/notch family members (Houde, et al 2004) .
Two main pathways control apoptosis, the extrinsic and the intrinsic (or mitochondrial) pathways (Fig 1; see Cory et al. and Danial et al. for review) (Cory and Adams 2002; Danial and Korsmeyer 2004) . The extrinsic pathway involves the death receptor family which includes receptors which possess a death domain (DD) as Fas, TRAIL-R1 (DR4), TRAIL-R2 (DR5) or TNF-R1. Extrinsic apoptosis mediated by Fas inserm-00358309, version 1 -3 Feb 2009 or TRAIL has been studied in MM. Purified MMC present a variable sensitivity to Fas but unseparated MMC are Fas resistant (Westendorf, et al 1995) and exogenous cytokines as IL-6, being one of the main myeloma growth factors , reverse Fas-mediated apoptosis in sensitive MMC (Chauhan, et al 1997) . MMC are highly and specifically sensitive to TRAIL-mediated apoptosis (Gazitt 1999; Mitsiades, et al 2001) . However, it has been suggested that the expression of decoy receptors for TRAIL could block TRAIL-mediated apoptosis (Locklin, et al 2007) .
TNF- is reported to be a growth factor for myeloma cell lines rather an apoptotic factor activating TNF-R1 receptor (Jourdan, et al 1999; Hideshima, et al 2001) .
The intrinsic pathway induces a dysfunction of some organelles, in particular mitochondrial dysfunction which results in a permeabilization of their outer membrane and the concomitant release of apoptogenic proteins into the cytosol allowing the execution of the apoptotic program (Fig 1) . The integrity of the outer mitochondrial membrane is controlled by the Bcl-2 family members (Kuwana and Newmeyer 2003) .
Today, about twenty Bcl-2 family members have been described, of which six have an anti-and 14 a pro-apoptotic activity (see list in Table I ). Therefore, the cell fate is highly dependent on the balance between these two groups of proteins. Several studies have elucidated the role of anti-apoptotic proteins to trigger myeloma cell survival. Most studies confirmed the anti-apoptotic protein Mcl-1 to be essential for the survival of MMC (Puthier, et al 1999; Jourdan, et al 2000; Spets, et al 2002; Zhang, et al 2002) . Our group has shown that among 10 Bcl-2 family proteins, only
Mcl-1 is upregulated by IL-6 and IFN- in several myeloma cell lines . In addition, a constitutive expression of Mcl-1 can prevent MMC from growth factor deprivation induced apoptosis . The role of two further anti-apoptotic members, Bcl-2 and Bcl-xL, remains currently unclear. Their regulation
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by IL-6 is controversial and addition of antisense to Bcl-xL or Bcl-2 did not lead to myeloma cell apoptosis, unlike antisense to Mcl-1 (Derenne, et al 2002) . Regarding the role of pro-apoptotic proteins of the Bcl-2 family, we found that IL-6, IFN- and IGF-1 did not regulate gene or protein expression of 5 pro-apoptotic proteins (Bax, Bak, Bid, Bcl-xS and Bad) . Some authors have suggested that Bad phosphorylation and sequestration by 14-3-3 proteins induced by activation of the PI3K/Akt pathway by myeloma growth factors is critical to prevent myeloma cell apoptosis (Ge and Rudikoff 2000) . More recently, Gomez-Bougie et al. have shown that the pro-apoptotic protein Bim was negatively regulated by IL-6 in MMC, and was strongly associated to Mcl-1 in viable cells (Gomez-Bougie, et al 2004) . These authors suggest that Bim is sequestered by Mcl-1 in viable cells and that in apoptotic conditions Noxa, a "BH3 only" sensitizer proapoptotic protein, is upregulated and can displace Bim from Mcl-1, allowing Bim to activate Bak or Bax and to induce apoptosis (Gomez-Bougie, et al 2007) .
In the present study, we have evaluated the expression of genes coding for proteins linked to extrinsic and intrinsic apoptosis, caspases and inhibitors of apoptosis proteins using Affymetrix microarrays. These expression were evaluated in purified MMC of a large panel of patients and compared with those of normal B cells, plasmablastic cells and bone marrow plasma cells.

Materials and Methods
Cell samples
MMC of 92 consecutive patients with previously-untreated MM were included in this study. This study is approved by the ethic committees at the University hospitals of Heidelberg (Germany) and Montpellier (France) and patients' written informed consent was given. These 92 patients were treated with high dose therapy (HDC) and autologous stem cell transplantation (ASCT). MMC were purified using an autoMACS with anti-CD138 MACS microbeads (Miltenyi-Biotec, Paris, France Bence-Jones lamda MM, and 4 non-secreting MM. We also used Affymetrix data of a cohort of 345 purified MMC from previously-untreated patients from the Arkansas research group (Little Rock). The patients were treated with total therapy 2 (Barlogie, et al 2006) and termed in the following LR-TT2 series. These data are publicly available in the NIH Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE2658. MMC were purified with anti-CD138 MACS microbeads (Miltenyi-Biotec).
For 5 patients with newly-diagnosed MM, bone marrow (BM) T cells (median percentage in BM cells: 8%), monocytes (6% in BM cells) and polymorphonuclear neutrophils (46% in BM cells) were purified as described .
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Osteoclasts and BM stromal cells (BMSC) obtained from MM patients were generated in vitro as described Moreaux, et al 2005) .
Normal BM plasma cells (BMPC) were obtained from healthy donors after informed consent was given. Plasma cells were purified with anti-CD138 MACS microbeads. were obtained and generated in vitro from purified CD19 + peripheral blood B cells obtained from healthy donors as previously described (Tarte, et al 2002) . Normal testis RNA samples were purchased from CliniSciences (Montrouge, France).
Microarray hybridization
RNA was extracted with the RNeasy Kit (Qiagen, Valencia, CA, USA), the SV-total Arrays were scaled to an average intensity of 100. A threshold of 1 was assigned to values under 1. When different probe sets were available for a same gene, we chose the probe set yielding the highest variation coefficient.
Gene expression profiling (GEP) analysis
In the Affymetrix U133 Plus 2.0 microarrays, a gene is probed by eleven pairs of perfect-match/mismatch oligonucleotides randomly spread over the chip. The signed rank MAS5 algorithm decides after scanning if the corresponding gene can be inserm-00358309, version 1 -3 Feb 2009
statistically declared present (P call) or absent (A call), and delivers a weighted "fluorescence" signal. Gene expression data were analysed with our bioinformatic platform (RAGE, http://rage.montp.inserm.fr/) (Reme, et al 2008) and Amazonia (http://amazonia.montp.inserm.fr) (Assou, et al 2007) . Gene expression was assessed in 92 primary MMC samples, 7 BMPC samples, 6 MBC samples, 7 PPC samples from healthy donors and 5 testis samples with U133 Plus 2.0 microarrays.
Hierarchical clustering was performed with the Cluster and Treeview softwares from
Eisen (Eisen, et al 1998) . In order to study the role of genes involved in the extrinsic apoptotic pathway (death receptor family and their ligands), we also determined the We also used the GEP from 79 human normal tissues samples available from Hogenesch's group on a public database (Su, et al 2004) . These GEP data were determined with Affymetrix U133A and custom-designed GNFH1 arrays.
The same global scaling and normalization was used for these and our data.
Real-time RT-PCR analysis
Real-time RT-PCR analysis was done as previously described (Moreaux, et al 2004) .
The assays-on-demand primers and probes and the TaqMan Universal Master Mix were used according to the manufacturer's instructions (Applied Biosystems, Courtaboeuf, France). Real-time RT-PCR was performed using the ABI Prism 7000
Sequence Detection System and normalized to 2-microglobulin for each sample, and compared with the values obtained for a known positive control using the following formula 100/2 Ct where Ct = Ct unknown -Ct positive control.
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Statistical analysis
Statistical comparisons were made with the non-parametric Mann-Whitney test. Pvalues < .05 were considered as significant. To cluster the samples according to the similarity of their gene expression patterns, we performed an unsupervised principal component analysis (PCA) with our RAGE bioinformatics platform (http://rage.montp.inserm.fr/). The statistical significance of differences in event free
and overall survivals between groups of patients was estimated by the log-rank test.
For survival analysis, we used as a test group our MM series of 171 previouslyuntreated patients whose MMC GEP were determined with U133 Affymetrix microarrays. We also used as a validation group the independent LR-TT2 series of 345 previously-untreated patients from the Arkansas group whose GEP data, performed with U133 Affymetrix microarrays, are publicly available in the NIH Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE2658.
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Results
The use of Affymetrix microarrays to investigate the various pathways involved in survival/apoptosis of normal B cells, normal and tumor plasma cells.
We investigated the expression of genes coding for molecules involved in the extrinsic and intrinsic apoptotic pathways using Affymetrix microarrays. A consensuslist of genes associated to apoptosis (Table I) 
Death receptor family
Fas and Fas ligand
FAS expression is higher in PPC compared to MBC and BMPC and is significantly lower in MMC compared to PPC or BMPC (Figs 2 and S1, Table II FADD, as adapter molecule for the death receptor family allows the recruitment and activation of caspase 8 upon activation of death receptors (Fig 1) . FADD expression is high in normal PPC that rapidly undergo apoptosis (Tarte, et al 2002) compared to MBC, BMPC and MMC samples (ratio ≥ 2.2; P < .003) (Figs 2 and S1, Table II) .
CFLAR/FLIP, an inhibitor of caspase 8 activation, is expressed by all samples, but lower in MBC compared to normal and tumor plasma cells (P < .01, Figs 2 and S1).
The Bcl-2 family
Genes coding for anti-apoptotic proteins
The expression of the 6 known anti-apoptotic members (Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bfl1/A1 and Bcl-B) can be evaluated with Affymetrix microarrays (Figs 3 and S2 ).
BCL2L10/BCL-B was absent in all samples. This probe set works as BCL2L10 is highly expressed in oocytes (data not shown) (Assou, et al 2006) . BCL2L2/BCL-W is weakly expressed in all samples and there was no present call for this probe set in 54 % of MMC samples.
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As shown in Fig S2, four genes -BCL2, BCL2L1, MCL1, BCL2A1 -showed a "present" call in the majority of samples of a given cell category: BCL2 and MCL1 expressions are significantly higher in normal or malignant plasma cells compared to PPC and MBC (P ≤ .03, Table II ). BCL2L1 expression is higher in plasmablasts and normal or malignant plasma cells compared to MBC (P ≤ .003). BCL2A1 is weaker expressed in early and late normal and malignant plasma cells compared to MBC (Table II) . This fits well with the known repression of BFL1/A1 by the PRDI-BF1/Blimp1 plasma cell transcription factor (Calame, et al 2003; Tarte, et al 2004) .
Genes coding for pro-apoptotic proteins
The 16 pro-apoptotic protein genes reported in Table I (Su, et al 2004) , suggesting that there is a defect in the probe sets (data not shown). This is likely the case for BAX, BAD, BIK probe sets whose gene and protein expression have been already documented in MM (Egle, et al 1997; Jourdan, et al 2000; Renner, et al 2000; Spets, et al 2002) .
The overall message is that BCL2L11, BNIP3L and BCL2L13 are expressed by all MBC, PPC, BMPC and MMC without major difference in expression level between these populations. BID is overexpressed in normal and malignant plasma cells compared to MBC and PPC (P ≤ .003). Bid thereby constitutes a link between extrinsic and intrinsic apoptosis (Fig 1) , thus a high expression of Bid could contribute to apoptosis of MMC induced by activation of the death receptors. Interestingly, BNIP3 is variably expressed in MMC but is significantly decreased in MMC compared inserm-00358309, version 1 -3 Feb 2009
to BMPC (Table II) . 31% of MM samples do not express the gene. BAK1 and BCL2L12 have a present call in respectively 20% and 89% of MMC. They are both increased in PPC compared to BMPC and MMC as BNIP3 (P < .013). Both HRK and PMAIP1 are heterogeneously expressed in MMC. Expression of PMAIP1 is higher in MBC than in normal or malignant plasma cells (Table II) .
APAF1 and mitochondrial mediators of apoptosis
As shown in Fig 1, several proteins are involved in the control of the mitochondrial apoptosis pathway. The expression of these genes is shown in Figs 3 and S4. APAF1, a critical mediator of caspase 9 activation, was lower expressed in primary MMC compared to MBC, PPC and BMPC (Table II) . CYCS, DIABLO or HTRA2 genes were expressed in all normal or malignant plasma cells as well as in PPC or MBC (Figs 3 and S4) . AIFM1 expression was significantly increased in PPC compared to MBC, BMPC and MMC (Table II) .
Caspase gene expression
11 caspase genes can be interrogated with Affymetrix microarrays (Figs 3 and S5 ).
Except for CASP5 and CASP14, these genes are expressed in at least one B or plasma cell sample type. Of interest, the initiator CASP8 and CASP9 are higher expressed in MBC compared to normal or malignant plasma cells (Table II) . To the contrary, there is no present call for CASP10 gene in MBC. CASP2, CASP3, CASP6 (Table II) and CASP7 are increased in PPC compared to MBC, BMPC and MMC (P < .01). CASP5 is absent in all B cell lineage samples but is present in myeloid samples (data not shown).
Inhibitors of apoptosis (IAP/BIRC family)
Affymetrix microarrays make it possible to interrogate 6 members of the IAP family, known to block caspase activity (Figs 3 and S6) . BIRC5/SURVIVIN is highly
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expressed in PPC and lacking in MBC and BMPC (Table II) . It is present in 26% of primary MMC in our HM series and in 12% of patients in the LR-TT2 series.
BIRC2/CIAP1, XIAP/BIRC4
and BIRC6/APOLLON are highly expressed in all MBC-, PPC-and BMPC-samples as well as MMC. NAIP/BIRC1 is weakly expressed and has an absent call in the majority of samples from B cell lineage, in contrast to CD14, CD15 or osteoclast-samples, which have a higher expression (data not shown).
BIRC3/CIAP2
is not expressed in PPC, highly expressed in BMPC (Table II) 
Principal component analysis of normal and malignant plasma cell samples using Affymetrix probe sets linked with survival/apoptosis
The analysis above makes it possible to select 40 out of the 58 Affymetrix probe sets interrogating the pathways regulating extrinsic and intrinsic apoptosis that are expressed in at least one B-or plasma-cell lineage population (normal MBC, PPC, BMPC and MMC). We consecutively performed a principal component analysis (PCA) of the gene expression of these 40 probe sets with MBC, PPC and BMPC ( Fig   5A) . The first two principal components (PCA1 and PCA2) accounted for 56% and 21% of the sample variance, respectively. Of interest, these 40 probe sets made it possible to separate MBC, PPC and BMPC in 3 homogeneous clusters. In the figure, the lines represent the contribution of each of the 40 probe sets to design the cell clusters in the PCA data space. Each probe set is represented by a line from the inserm-00358309, version 1 -3 Feb 2009 origin whose direction indicates which cluster or region is most contributed to and length indicates the strength of this contribution (i.e. the correlation coefficient of the probe set with the theoretical probe set built by PCA analysis). For 13 probe sets, e.g. TNFRSF10D, CASP1, CASP4, CASP10, BCL2L1, BAK1, BNIP3, BCL2L12, BIRC2, CYCS, APAF1, DIABLO and HTRA2, the "probe set line" is at a comparable distance to two clusters, indicating a contribution to both clusters. For the remaining 27 probe sets defining only one cluster, the correlation coefficient ranged from 0.3 to 1, of which 18 probe sets (listed in Fig. 5A ) had a correlation coefficient higher than 0.8. According to the ranking of the correlation coefficients that indicates the input of a probe set to characterize a cell cluster, the MBC cluster is characterized by Regarding the extrinsic apoptotic pathway, an elevated expression of TNFSF10/TRAIL and TRAIL receptors in MMC is observed suggesting an autocrine apoptotic loop could occur. Likely, this apoptotic loop is blocked by decoy receptors.
In particular, TNFRSF10D is highly expressed by MMC. Osteoprotegerin that is highly expressed by MSC also acts as a soluble decoy receptor and may block TRAIL induced MMC apoptosis (Shipman and Croucher 2003) . These TRAIL decoy receptors could hamper the use of TRAIL in MM therapy suggested by several authors (Gazitt 1999; Mitsiades, et al 2001) . Of interest, agonist antibodies to TRAIL receptors induced MMC apoptosis and could bypass the inhibition of TRAIL-induced apoptosis by decoy receptors as soluble osteoprotegerin (Menoret, et al 2006; Locklin, et al 2007) . An elevated expression of CFLAR/FLIP in MMC samples could also confer resistance to apoptosis induced by activation of the extrinsic apoptotic pathway. Indeed, Mitsiades et al. (Mitsiades, et al 2002) have reported that MMC resistance to TRAIL to be associated with a low pro-caspase 8/Flip ratio although these results remain controversial (Spencer, et al 2002) .
Among the Bcl-2 family members, we did not observe a significant difference in DNA methylation in the region around the BNIP3 transcription start site, associated with the silencing of the gene in primary MMC from three out of 14 patients with MM (21%) (Murai, et al 2005) .
Regarding the Durie Salmon stage of the patients with MM, only 3 genes out of 40 genes studied were differentially expressed: CASP2, CASP6 and BIRC5 (data not shown). The expression of the 3 genes were higher in stage II or III than in stage I MM patients (P ≤ .033, P ≤ .044 and P ≤ .018 respectively). Noteworthy, this result is in agreement with the poor prognosis value of CASP2 and BIRC5 in the 2 independent series of patients. The poor prognosis value of CASP2 encoding gene can be explained by the non-apoptotic functions mediated by the caspase recruitment domain (CARD) in the pro-domain of caspase 2, in particular, by the recruitment of TNF receptor-associated factor 2 (TRAF2) and receptor-interacting protein 1 (RIP1) in a caspase 2 complex capable to induce activation of NF-kB (Lamkanfi, et al 2005) . Recently, survivin expression has been shown to be correlated to MM progression (Romagnoli, et al 2007) and to a poor outcome of patients with multidrug-resistant 1 protein increase after chemotherapy (Nakagawa, et al 2006) .
In conclusion, this study provides a general view of the contribution of the expression of genes in delineating normal and malignant plasma cells. Out of 40 contributive genes encoding for the major proteins involved in the extrinsic and intrinsic apoptosis pathways, 27 efficiently separate normal memory B cells, plasmablastic cells and bone marrow plasma cells. A high expression of TNFSF10 delineates a malignant cluster comprising about 50% of the patients. Out of the 40 genes, 2 genes -CASP2
and BIRC5/SURVIVIN -had poor prognosis in 2 independent patients' series and these 2 genes are overexpressed in normal plasmablastic cells. 
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